Navigation Links
Triple Negative Cancer Research Could Benefit All Breast Cancer Patients
Date:1/31/2011

FREDERICKSBURG, Va., Jan. 31, 2011 /PRNewswire/ -- Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

"Understanding how triple negative cancers spread in the absence of normal growth factors may give us insight into how other types of breast cancer grow and spread even after treatment," Dr. Tucker explains.

Recent research has shown that a new class of drugs, PARP inhibitors, can be combined with chemotherapy to kill more triple negative breast cancer cells. Research also indicates that platinum compounds, a type of chemotherapy not typically prescribed for breast cancer, may be useful in treating triple negative disease.

Currently, two trials offered at Fredericksburg Oncology focus on triple negative disease.

  • CALGB 40603:  Pre-operative (neoadjuvant) chemotherapy for triple-negative breast cancer involving platinum chemotherapy (carboplatin) and bevacizumab.
  • NCCTG N0937:  Platinum chemotherapy (Cisplatin) and brostacillin for metastatic triple-negative breast cancer

An estimated 15 percent of breast cancers are triple negative, meaning they do not have receptors for estrogen, progesterone, and for the growth factor receptor HER2.  Breast cancer treatments such as Tamoxifen, Arimidex, Femara, and Herceptin which target these molecules are therefore not helpful against triple negative disease. Standard chemotherapies can be used in triple negative breast cancer, but they may not be as effective as they are for more common breast cancers.

For more information about clinical trials offered through Fredericksburg Oncology, visit http://fredericksburgoncology.com/wp/about-clinical-trials/.  Email regarding clinical trials can be sent to info@fred-onc.com or call (540) 368-0500.

About Fredericksburg Oncology

Fredericksburg Oncology specializes in providing high quality treatment for the medical and emotional needs of cancer patients. Since 2006, the practice also has been committed to providing clinical research. It is located at 111 Park Hill Drive, Suite B, Fredericksburg, VA 22401 near Mary Washington Hospital. For more information call (540) 368-0500 or visit www.fredericksburgoncology.com.

Dr. Frederick C. Tucker, Jr. is board certified in oncology, internal medicine, and psychiatry. He also is a writer and speaker on cancer-related topics. To read Dr. Tucker's recent commentary, visit http://fredericksburgoncology.com/wp/topics/news/ or connect with him on Facebook.


'/>"/>
SOURCE Fredericksburg Oncology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
5. The Hepatitis C Virus Drug Market Will More Than Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
6. The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
7. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
8. EndoChoice® Triples Facility Space to Address Growing Customer Base
9. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... enterprise Data Center Infrastructure Management solutions, announces today the availability of its ... in the area of capacity management and optimization, providing new analytical capabilities ...
(Date:4/28/2016)... ... ... One way to ignore solid evidence is to dismiss research because, “it ... baby out with the bathwater when we ignore all studies because some are fatally ... making better use of education policy research. , “When readers heed basic cautions, research ...
(Date:4/28/2016)... ... ... Card reminds us that May is National Stroke Awareness Month. According to the Centers ... in the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes ... old. A stroke is when blood flow to the brain is blocked or when ...
(Date:4/28/2016)... Phoenix, AZ (PRWEB) , ... ... ... of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced ... The platform will provide efficient access to medical knowledge, educational resources, and ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ ... states studied, the Workers Compensation Research Institute (WCRI) announced, and that costs ... CompScope™ Benchmarks for Kentucky, 16th Edition , found that indemnity costs per claim and ...
Breaking Medicine News(10 mins):